Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

This publication has 18 references indexed in Scilit:

• Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
  New England Journal of Medicine, 2004
• Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
  Journal of Clinical Oncology, 2004
• EGFR and cancer prognosis
  European Journal of Cancer, 2001
• The EGF receptor family as targets for cancer therapy
  Oncogene, 2000
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
  The Lancet, 1998
• Epidermal growth factor (EGF) Increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704
  European Journal of Cancer, 1996
• In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals
  Clinical & Experimental Metastasis, 1995
• Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
  Cancer Chemotherapy and Pharmacology, 1995
• Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients
  Journal of Chromatography B: Biomedical Sciences and Applications, 1992
• The epidermal growth factor receptor as a multifunctional allosteric protein
  Biochemistry, 1988